new glp-1 receptor agonists Guidelines for Type 2 Diabetes in 2025 GLP-1 receptor agonists and next-generation

Nature 528, 262266

Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials

Evidence supports an indirect relationship mediated by weight reduction, improved insulin sensitivity, and normalization of hormonal and inflammatory pathways

Importantly, the review also notes that individual responses to incretin-based therapies can vary substantially, and weight regain commonly occurs if treatment is discontinued, highlighting the chronic nature of obesity management

AIWG was more pronounced in first-episode patients, individuals with schizophrenia, and longer duration of AP use